Recent Updates
Recently added Catalysts
ARDX Negative Sentiment Score: 25/100

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Ardelyx, Inc. on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board. The complaint follows a significant drop in Ardelyx’s stock price after the company disclosed it would not apply to include XPHOZAH in the TDAPA program, contrary to prior statements made by its executives. Investors are being encouraged to reach out to the law firm for more information on the developments regarding their rights and the ongoing investigation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ardelyx's stock price dropped significantly by 30.25% following the news.
  • A class action complaint was filed against Ardelyx, indicating potential legal issues.
  • The company misled investors regarding the inclusion of XPHOZAH in TDAPA, breaching fiduciary duties.

Full Press Release Details

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of long-term stockholders following a class action complaint that was filed against Ardelyx on August 16, 2024, with a Class Period from October 31, 2023 to July 1, 2024. Our investigation concerns whether the board of directors of Ardelyx have breached their fiduciary duties to the company.
The Complaint alleges that, in its Forms 10-Q filed on October 31, 2023, and May 2, 2024, and in its Form 10-K filed on February 22, 2024, Ardelyx indicated that it would apply to include XPHOZAH in TDAPA. Further, on an earnings call on May 2, 2024, Defendant Michael Raab advised analysts that "our intent is to enter TDAPA." But then on July 2, 2024, Ardelyx shocked investors by disclosing that it had decided not to apply to include XPHOZAH in TDAPA.
Upon the above news, Ardelyx's stock price fell $2.29 per share, or 30.25%, to close at $5.28 per share on July 2, 2024.
If you are a long-term stockholder of Ardelyx, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the investigation against Ardelyx, Inc. about?

Bragar Eagel & Squire is investigating possible claims against Ardelyx for breaching fiduciary duties.

What triggered the investigation into Ardelyx?

The investigation follows a class action complaint filed against Ardelyx on August 16, 2024.

When was Ardelyx's stock price significantly affected?

Ardelyx's stock dropped by 30.25% on July 2, 2024, after surprising investors.

What announcement shocked Ardelyx investors?

On July 2, 2024, Ardelyx announced it would not apply to include XPHOZAH in TDAPA.

How can I contact Bragar Eagel & Squire?

You can email investigations@bespc.com or call (212) 355-4648 for inquiries.

Last updated: Oct 23, 2024